Q-omics provides the consensus-scored PEX12 profile across patient tissues and cancer cell-line models. PEX12 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PEX12 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, PEX12 RNA expression shows 20,047 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where PEX12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PEX12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PEX12 survival associations across molecular data types. PEX12 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PEX12 RNA expression–survival associations across cancer types. High PEX12 expression shows unfavorable associations in KIRP, but favorable associations in KIRC, ESCA, BRCA, ACC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PEX12 RNA expression.
This table summarizes PEX12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PEX12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PEX12 shows lower tumor expression in THCA, UCEC and KICH and higher tumor expression in HNSC, CHOL and LIHC. The THCA box plot shows higher PEX12 RNA expression in normal versus tumor tissue (log2 FC = −1.153, t-test p < 0.001).
This table shows molecular features associated with PEX12 in patient tissues and cancer cell lines. In patient samples, PEX12 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PEX12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
